Moderna (MRNA)
Nasdaq Market Closed
Moderna, Inc. is a biotechnology company built around messenger RNA, or mRNA, medicines. The company became globally known after its COVID-19 vaccine demonstrated the speed and scalability of mRNA technology, moving Moderna from a platform-stage biotech into a commercial vaccine producer.
Moderna continues to apply mRNA across infectious disease, oncology, rare genetic disease and other therapeutic areas. Its research model uses mRNA instructions to direct cells to produce proteins that can trigger immune responses or address disease biology. The company’s pipeline includes multiple clinical programs, and its commercial prospects depend on vaccine demand, new product approvals and the ability to extend mRNA beyond COVID-19. MRNA is therefore both a biotech platform investment and a test of how broadly mRNA medicines can be commercialized.
Last updated
- Market Cap
- 19.47B
- P/E
- —
- P/FCF
- —
- P/S
- 8.75
- Enterprise Value
- 18.16B
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 325 BINNEY STREET, CAMBRIDGE, MA, 02142
Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
CytomX Therapeutics to Present at Upcoming June Investor Conferences
Hantavirus outbreak: these 3 stocks are poised to rip higher
Moderna Stock Climbs After Hantavirus Vaccine: Data Triggers Analyst Price Target
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider
CytomX Therapeutics to Present at Upcoming February Conferences
Lipid Nanoparticle Manufacturing Market: An 18.9% CAGR Market Driven by Nucleic Acid Therapies
Moderna Stock Rallies as Oncology Results Improve the Platform’s Value Case
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?
Nanobiotechnology Market to Hit USD 420.2 Billion by 2034, Fueled by 2025 Traffic Growth and Strategic Material & Product Innovations
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
Seasonal Vaccines Market Accelerating Growth and Rising Opportunities Through 2035
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
6 Healthcare Stocks Positioned to Soar After Trump-Pfizer Deal
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 19.47B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 18.16B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.63
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 8.75
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -5.72
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 8.16
- EPS
- -8.05
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -1.6B
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -43.12%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -27.8%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.08
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.41
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.35
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.8
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 7.02M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 49.06
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 389M | 678M | 1.02B | 142M | 108M |
| Gross profit | -566M | 226M | 809M | 23M | 18M |
| Operating income | -1.39B | -857M | -260M | -907M | -1.05B |
| EBITDA | -1.33B | -790M | -208M | -850M | -1.01B |
| Net income | -1.34B | -826M | -200M | -825M | -971M |
| Basic EPS | -3.4 | -2.11 | -0.51 | -2.13 | -2.52 |
| Diluted EPS | -3.4 | -2.11 | -0.51 | -2.13 | -2.52 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 11.49B | 12.34B | 12.14B | 12.01B | 12.7B |
| Total liabilities | 4.08B | 3.69B | 2.81B | 2.61B | 2.64B |
| Total equity | 7.41B | 8.65B | 9.33B | 9.4B | 10.07B |
| Cash & equivalents | 1.91B | 2.6B | 1.13B | 1.28B | 1.62B |
| Current assets | 5.77B | 6.54B | 6.6B | 6.17B | 6.77B |
| Current liabilities | 2.4B | 1.99B | 1.68B | 1.57B | 1.6B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -630M | 930M | -847M | -919M | -1.04B |
| Investing cash flow | -76M | -48M | 700M | 564M | 730M |
| Financing cash flow | 17M | 581M | -1M | 9M | 4M |
| Change in cash | -688M | 1.46B | -147M | -345M | -303M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — AFEYAN NOUBAR | View Filing | |
| form 4 | Form 4 — AFEYAN NOUBAR | View Filing | |
| form 4 | Form 4 — AFEYAN NOUBAR | View Filing | |
| form 4 | Form 4 — AFEYAN NOUBAR | View Filing | |
| form 4 | Form 4 — AFEYAN NOUBAR | View Filing | |
| form 4 | Form 4 — AFEYAN NOUBAR | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| edgar index | 8-K — Moderna, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — AFEYAN NOUBAR | View Filing | |
| form 4 | Form 4 — Tallett Elizabeth E | View Filing | |
| form 4 | Form 4 — Nader Francois | View Filing | |
| form 4 | Form 4 — Nader Francois | View Filing | |
| form 4 | Form 4 — NABEL ELIZABETH G | View Filing | |
| form 4 | Form 4 — Horning Sandra | View Filing | |
| form 4 | Form 4 — Horning Sandra | View Filing | |
| form 4 | Form 4 — Hussain Abbas | View Filing | |
| form 4 | Form 4 — Rubenstein David M. | View Filing | |
| form 4 | Form 4 — Rubenstein David M. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 8-K — Moderna, Inc. | View Filing | |
| edgar index | 10-Q — Moderna, Inc. | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Hussain Abbas | View Filing | |
| form 4 | Form 4 — Tallett Elizabeth E | View Filing | |
| form 4 | Form 4 — Tallett Elizabeth E | View Filing | |
| form 4 | Form 4 — Nader Francois | View Filing | |
| form 4 | Form 4 — Nader Francois | View Filing |